[HIGHLIGHTS] FDA postpones approval of Eli Lilly's experimental Alzheimer's drug

FDA postpones approval of Eli Lilly's experimental Alzheimer's drug. The regulatory agency was expected to make a decision on approving the drug donamemab next week.

But in an “unexpected” move he decided to get an independent opinion before making a final decision. . By Berkeley Lovelace Jr. - NBC News The Food and Drug Administration (FDA) has postponed the approval deadline for donanemab. Lilly applied to the FDA for approval of the drug in July.